Prostatype Genomics enters collaboration with Spanish Eurofins Megalab

Wed, Mar 29, 2023 15:42 CET

Prostatype Genomics begins collaboration with Eurofins Megalab, leader in clinical analysis on the Spanish laboratory market and part of Eurofins, one of the world's largest laboratory groups present in Europe, USA, Asia, and Latin America. The agreement means that Eurofins Megalab will manage all steps in the laboratory process required to analyze the Prostatype® test on the Spanish and Portuguese markets. The collaboration is another step in Prostatype Genomics' work to further accelerate commercialization in Europe. The agreement will enter into force immediately.

Prostatype Genomics begins collaboration with Eurofins Megalab, leader in clinical analysis on the Spanish laboratory market and part of Eurofins, one of the world's largest laboratory groups present in Europe, USA, Asia and Latin America. The agreement means that Eurofins Megalab will manage all steps in the laboratory process required to analyze the Prostatype® test on the Spanish and Portuguese markets. The collaboration is another step in Prostatype Genomics' work to further accelerate commercialization in Europe. The agreement will enter into force immediately.

Following previously communicated collaborations regarding priority markets, this means that Eurofins Megalab will manage the entire laboratory process on the Spanish and Portuguese markets, from initial contacts with healthcare providers to performing the gene analysis in their labs and reporting the results in accordance with Prostatype Genomics' quality-assured processes.

Fredrik Persson, Prostatype Genomics' CEO says: "The collaboration with Megalab is an important step for us in Spain, which is not only a large market with about 35,000 men diagnosed with prostate cancer every year, but also a market that in many ways is at the forefront in Europe. Megalab is a leading laboratory company in the Spanish market and is part of Eurofins' global organization, which creates interesting opportunities to find laboratory partners in other prioritized markets as well.”

Eurofins Megalab has a well-developed network of urologists and works in more than 50 private hospitals in Spain. It provides opportunities for a fast sales development, since in addition to cooperation in laboratory services, it also includes cooperation between Prostatype Genomics' local Spanish organization and the commercial structures of Eurofins Megalab in Spain, which gives a great advantage to the commercialization of the Prostatype® test.

Dr. Mamen Sánchez-Hombre, Director of the Genetics business area at Eurofins Megalab says: "Prostate cancer is a disease that affects many Spaniards, and where there is a great need for better decision support, both for doctors and patients. Prostatype® is an innovative test that fills a clinical need and, in an educational way, gives patients the opportunity to better understand what risk they are at, and which treatment is right for them. With 30 years of experience in the Spanish market where we carry out and analyse more than 20,000 laboratory tests per day, Eurofins Megalab is an excellent partner for Prostatype Genomics in the work to commercialize Prostatype® in Spain and Portugal."

About Eurofins

Eurofins was founded in 1987 and today is one of the largest laboratory networks in the world with more than 61,000 employees in 61 countries and more than 900 laboratories worldwide. Approximately 450 million tests of various kinds are performed annually.

Prostatype Genomics enters collaboration with Spanish Eurofins Megalab

Subscribe